Winning FDA support for a clinical development program does not mean persuading the Agency to endorse a sponsor’s preferred strategy. Rather, it means creating a development program that is scientifically justified, clinically meaningful, operationally feasible, and supported by a clear regulatory rationale. FDA encourages interaction with sponsors at important stages of development, including before an Investigational New Drug (IND) submission and at later development milestones. A strong FDA regulatory strategy begins with understanding the questions that FDA reviewers are likely to raise. Sponsors should establish a clear development rationale covering the target population, mechanism of action, dose and exposure, safety considerations, clinical endpoints, statistical approach, and overall benefit-risk framework. The objective is not simply to present favorable data but to demonstrate how the proposed evidence will address the regulatory question of whether the product can be shown to be safe and effective for its intended use.

Early FDA engagement can be particularly valuable when important elements of the development plan remain uncertain. Depending on the product and development stage, sponsors may seek a pre-IND meeting or other formal interaction to discuss nonclinical requirements, initial clinical study design, manufacturing and quality considerations, and the information needed to support the IND. For novel therapies regulated by CBER’s Office of Therapeutic Products, FDA also provides the INTERACT pathway for appropriately timed early discussions before definitive toxicology studies. The quality of the meeting package can significantly influence the usefulness of the interaction. Sponsors should avoid presenting an unfocused list of broad questions. Instead, each question should identify the regulatory issue, summarize the relevant evidence, explain the sponsor’s proposed approach, and ask FDA for specific feedback. FDA’s current formal-meeting guidance, finalized in August 2026, emphasizes structured procedures for requesting, preparing, conducting, and documenting meetings.

A credible clinical trial design should also reflect FDA’s expectations for scientifically sound evidence generation. Sponsors need to justify endpoint selection, control groups, estimands where relevant, statistical methods, patient population, sample size, and handling of missing data. Multiple endpoints, for example, can increase the possibility of misleading findings if multiplicity is not appropriately addressed. FDA guidance emphasizes the importance of prospectively planned approaches for managing such statistical issues. For innovative programs, early discussion becomes even more important. Sponsors developing products that rely on novel biomarkers or surrogate endpoints may need to establish why the proposed endpoint is appropriate for the intended context of use. FDA provides specific opportunities for discussing novel surrogate endpoints through Type C meetings, with the objective of identifying evidentiary gaps and determining what additional work may be necessary.

Another important consideration is the growing emphasis on risk-based clinical development and quality by design. FDA’s September 2025 finalization of ICH E6(R3) Good Clinical Practice reinforces flexible, risk-based approaches while maintaining participant protection and reliable trial results. Sponsors should therefore demonstrate that critical-to-quality factors have been identified and that trial risks are proportionately controlled rather than relying solely on traditional procedural compliance. Regulatory engagement is also evolving as sponsors increasingly use sophisticated analytical approaches. FDA’s Model-Informed Drug Development program and the 2026 availability of ICH M15 provide additional frameworks for discussing model-informed approaches, including model evaluation, documentation, and assessment of model risk. Similarly, FDA continues to support interaction around complex innovative trial designs, including adaptive and Bayesian approaches.

One of the greatest FDA compliance risks is treating regulatory advice as a substitute for sponsor responsibility. FDA can provide feedback and regulatory advice, but the sponsor remains responsible for its development program. FDA also notes that meeting requests may not always be granted because of Agency resources and competing priorities. Sponsors should therefore maintain ownership of the scientific rationale, document FDA feedback carefully, evaluate subsequent evidence, and explain any material departures from previously discussed approaches.

For pharmaceutical, biotech, medical device, and clinical research organizations, effective FDA communication should continue beyond individual meetings. A development program benefits from a documented regulatory strategy that connects meeting outcomes to protocol development, statistical planning, safety monitoring, data standards, manufacturing activities, and eventual submission planning. This creates consistency across functions and reduces the risk of contradictory positions being presented to FDA at different stages. Ultimately, FDA support for clinical development is strengthened when sponsors demonstrate scientific discipline, transparency, preparation, and a willingness to address weaknesses. The most productive regulatory interactions are evidence-driven conversations in which the sponsor clearly understands both the strengths and limitations of its program. Rather than asking FDA to simply validate a predetermined plan, sponsors should use regulatory interactions to test assumptions, identify evidence gaps, and improve the probability that the resulting development package will answer the Agency’s key questions.

Conclusion:

A successful clinical development program earns FDA confidence through scientific credibility, focused regulatory engagement, robust evidence generation, and transparent risk management. Sponsors that engage early, ask precise questions, respond constructively to regulatory feedback, and maintain a coherent evidence strategy are better positioned to navigate development challenges and build a submission capable of supporting informed FDA review.